These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1829022)

  • 41. [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
    Kojima T; Suzumura K; Kanemitsu T; Miyashita A; Inamura Y; Owa Y; Naruse T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):547-51. PubMed ID: 9530361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation.
    Rustum YM
    Oncology; 1997; 54 Suppl 1():7-11. PubMed ID: 8978578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
    Fukushima M; Satake H; Uchida J; Shimamoto Y; Kato T; Takechi T; Okabe H; Fujioka A; Nakano K; Ohshimo H; Takeda S; Shirasaka T
    Int J Oncol; 1998 Oct; 13(4):693-8. PubMed ID: 9735397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hematologic effects of interleukin-1 beta, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor in tumor-bearing mice treated with fluorouracil.
    Moore MA; Stolfi RL; Martin DS
    J Natl Cancer Inst; 1990 Jun; 82(12):1031-7. PubMed ID: 1693405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice.
    Waidmann M; Bechtold O; Frick JS; Lehr HA; Schubert S; Dobrindt U; Loeffler J; Bohn E; Autenrieth IB
    Gastroenterology; 2003 Jul; 125(1):162-77. PubMed ID: 12851881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatoprotective Effect of Carboxymethyl Pachyman in Fluorouracil-Treated CT26-Bearing Mice.
    Wang C; Huo X; Gao L; Sun G; Li C
    Molecules; 2017 May; 22(5):. PubMed ID: 28481246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of rhG-CSF scheduling on megakaryocytopoietic recovery following 5-fluorouracil-induced hematotoxicity in splenectomized B6D2F1 mice.
    Scheding S; Media JE; Nakeff A
    Stem Cells; 1998; 16(2):144-51. PubMed ID: 9554039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipopolysaccharide-induced non-specific resistance to systemic Escherichia coli infection in mice.
    Vuopio-Varkila J; Nurminen M; Pyhälä L; Mäkelä PH
    J Med Microbiol; 1988 Mar; 25(3):197-203. PubMed ID: 3279215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
    Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
    Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil.
    Kanai F; Kawakami T; Hamada H; Sadata A; Yoshida Y; Tanaka T; Ohashi M; Tateishi K; Shiratori Y; Omata M
    Cancer Res; 1998 May; 58(9):1946-51. PubMed ID: 9581837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model.
    Xu Q; Brabham JG; Zhang S; Munster P; Fields K; Zhao RJ; Yu H
    DNA Cell Biol; 2005 Jul; 24(7):470-5. PubMed ID: 16008516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells.
    Kato S; Hayashi S; Kitahara Y; Nagasawa K; Aono H; Shibata J; Utsumi D; Amagase K; Kadowaki M
    PLoS One; 2015; 10(1):e0116213. PubMed ID: 25565296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rate of DNA synthesis as an indication of drug toxicity and as a guide for scheduling cancer therapy.
    Wheeler GP; Alexander JA
    Cancer Treat Rep; 1978 May; 62(5):755-69. PubMed ID: 657161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The study for the immuno-protection of E. coli O157:H7 outer membrane protein].
    Zhang Y; Lu SQ; Zhang YZ; Zhao BX; Xu JG
    Zhonghua Yi Xue Za Zhi; 2004 Jan; 84(1):58-62. PubMed ID: 14990161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of Escherichia coli O157:H7 infection in gnotobiotic mice associated with Bifidobacterium strains.
    Yoshimura K; Matsui T; Itoh K
    Antonie Van Leeuwenhoek; 2010 Feb; 97(2):107-17. PubMed ID: 19911297
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
    Peer CJ; McManus TJ; Hurwitz HI; Petros WP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jun; 898():32-7. PubMed ID: 22565063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
    Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.